SCHEMBL24827912

SCHEMBL24827912

CC(C)N1CCC2(CC1)CN(c1ncc(CC(C)(C)C)cn1)C2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 11/20 0.39
▸ ALDH1A1 P00352 9/20 0.39
▸ HPGD P15428 8/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ USP2 O75604 2/20 0.39
▸ ACACB O00763 4/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ CYP1A2 P05177 3/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CYP2D6 P10635 5/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ CYP2C9 P11712 1/20 0.32
▸ OGA O60502 1/20 0.32
▸ TLR9 Q9NR96 1/20 0.32
▸ TLR8 Q9NR97 1/20 0.32
▸ TLR7 Q9NYK1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24827921 0.85 HSD17B10 (0.40) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL24828036 0.83 HSD17B10 (0.40) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL24828044 0.75 HSD17B10 (0.38) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL24827849 0.72 OGA (0.36) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL24827889 0.71 CYP3A4 (0.36) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL9944495 0.71 NPC1 (0.44) ALDH1A1ACACBKDM4ENPC1RAB9A
SCHEMBL26896471 0.70 ALDH1A1 (0.30) ALDH1A1TSHR
SCHEMBL22737504 0.70 HSD17B10 (0.43) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL21933955 0.69 HRH3 (0.48) OGA
SCHEMBL26788475 0.69 ALDH1A1 (0.33) HSD17B10ALDH1A1HPGDCYP3A4USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 — — US disclosed
US-11542266-B1 Substituted piperidines as BTK inhibitors HAISCO PHARMACEUTICALS PTE. LTD. (SG) 2023-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542266-B1 Substituted piperidines as BTK inhibitors BTK, BLK, SYK HSD17B10 4570/4885ALDH1A1 3396/4885HPGD 4322/4885
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR BTK, WEE1, WEE2 HSD17B10 1782/4885ALDH1A1 3737/4885HPGD 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback